Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Drug coated balloons are as good as stent implants for treating small blocked arteries

A removable balloon is as good as a permanent stent implant for opening small blocked arteries, according to late breaking results from the BASKET-SMALL 2 trial presented in a Hot Line Session today at ESC Congress 2018 and simultaneously published in The Lancet.

28 Aug 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials. Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator on the first trial and as local PI on three other trials.

30 Jun 2018

New findings could help fine-tune treatment for cancer patients

Cancer therapies that cut off blood supply to a tumor could be more effective in combination with existing chemotherapeutic drugs - according to new research from the University of East Anglia.

25 May 2018

Study reveals new protective mechanism for tumor cells in breast cancer

Greater knowledge of the mechanisms that contribute to the survival of tumor cells is key to vanquishing them.

25 May 2018

Researchers uncover novel approach for treating neuropathic pain

Neuropathic pain is the chronic, pathological pain that continues even when the cause of pain is removed. Causes include damage to nerve cells and medicines used to treat cancer.

4 May 2018

Treating metastatic breast cancer with immunotherapy

Breast cancer, in the stage with distant metastases, is an incurable disease with a 5 years survival rate of about 5-10%. Immunotherapy has recently improved survival in metastatic breast cancer patients with breast cancer harboring the expression of HER 2 receptor.

19 Mar 2018

UC Riverside researchers discover way to halt cancer metastasis

A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

23 Feb 2018

Study finds specific protein that plays role in breast cancer metastasis

Researchers from the University of Liverpool have found an explanation for how breast cancer spreads to the lungs, which could potentially hold the key to preventing the progression of the disease.

25 Jan 2018

HKBU experts develop new generation of smart anti-cancer drug molecules

The toxic nature of chemotherapy poses a great challenge to clinical treatment of cancer. A team of scholars from the School of Chinese Medicine of Hong Kong Baptist University devoted their efforts to the development of a new generation of smart anti-cancer drug molecules.

15 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Researchers find potential approach to prevent peripheral neuropathy

In discovering how certain chemotherapy drugs cause the nerve damage known as peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side effect of cancer treatment.

11 Oct 2017

FDA approved drug found to have anti-cancer activity against previously unknown targets

Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.

10 Oct 2017

Drug approved to treat parasitic infections also exerts anti-tumor effect on EOC cells

Osaka Researchers, in partnership with other Japanese and U.S. scientists, report a new gene target, KPNB1, for treatment against epithelial ovarian cancer (EOC).

28 Sep 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

MTI awards $25,000 grant to MDI Biological Laboratory scientist for peripheral neuropathy research

The Maine Technology Institute has awarded a $25,000 seed grant to Sandra Rieger, Ph.D., of the MDI Biological Laboratory to study peripheral neuropathy, a condition that causes pain, tingling and numbness in the hands and feet and affects an estimated 20 to 40 million Americans.

13 Sep 2017

Study finds potential preventive for chemotherapy-induced peripheral neuropathy

Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment that causes shooting or burning pain, numbness, tingling and cold sensitivity of the hands and feet for many cancer patients.

13 Sep 2017

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

A 14-year randomised trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery.

11 Sep 2017

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer

European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid.

4 Sep 2017